Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.

ČÍŽKOVÁ, M., M. DUJARIC, J. LEHMANN-CHE, V. SCOTT, O. TEMBO, B. ASSELAIN, J. PIERGA, M. MARTY, P. CREMOUX, F. SPYRATOS, I. BIECHE

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. British Journal of Cancer. 2013, 108(9), 1807-1809, ISSN: 0007-0920, PMID: 23612454,